Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
Highlights NO pathway as potential therapeutic target in CVD; leaves open optimal modulation strategies pending prospective trials.
Moncada et al. (2006) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: